← All trials
NCT02323685
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2014
- Primary completion
- Jun 1, 2016
- Completion date
- Oct 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Prolong PharmaceuticalsLead sponsor
- Washington University in St. LouisOverall official - principal investigator
- Washington University in St. LouisStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.